Healthcare -
Biotechnology - NASDAQ - US
$ 14.52
-6.02 %
$ 1.1 B
Market Cap
-5.04
P/E
CASH FLOW STATEMENT
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Nurix Therapeutics, Inc.
| Net Income | -194 M |
| Depreciation & Amortization | -1.97 M |
| Capital Expenditures | -9.27 M |
| Stock-Based Compensation | 33.9 M |
| Change in Working Capital | 0 |
| Others | -34.6 M |
| Free Cash Flow | -182 M |
Cash Flow
Millions
| Nov-2024 | Nov-2023 | Nov-2022 | Nov-2021 | Nov-2020 | Nov-2019 | Nov-2018 | |
|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||||
| Net Income | (193.6) | (143.9) | (180.4) | (117.2) | (43.2) | (21.7) | (9.4) |
| Depreciation & Amortization | (2.0) | 13.7 | 10.8 | 6.1 | 2.2 | 2.4 | 3.0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | (0.4) |
| Stock Based Compensation | 33.9 | 33.7 | 28.1 | 15.8 | 4.3 | 0.5 | 0.4 |
| Other Operating Activities | (11.0) | (4.9) | 0.6 | 1.8 | 0.3 | (0.1) | 6 K |
| Change in Working Capital | 0 | 20.1 | (19.0) | 9.1 | 36.4 | 19.5 | (25.3) |
| Cash From Operations | (172.6) | (81.4) | (159.8) | (84.4) | 80 K | 0.6 | (31.7) |
| INVESTING CASH FLOW | |||||||
| Capital Expenditures | (9.3) | (8.4) | (12.2) | (5.7) | (4.6) | (1.7) | (1.6) |
| Other Items | (248.4) | 76.7 | 39.4 | (102.6) | (249.9) | 10.1 | 41.6 |
| Cash From Investing Activities | (257.7) | 68.3 | 27.2 | (108.3) | (254.4) | 8.5 | 40.0 |
| FINANCING CASH FLOW | |||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 16 K | 2 K |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 7.2 | 3.2 | 97.8 | 3.7 | 120.9 | 0.1 | 0.5 |
| Cash From Financing Activities | 485.7 | 3.2 | 117.2 | 153.9 | 339.0 | 0.1 | 0.5 |
| CHANGE IN CASH | |||||||
| Net Change In Cash | 55.4 | (9.8) | (15.4) | (38.7) | 84.5 | 9.2 | 8.8 |
| FREE CASH FLOW | |||||||
| Free Cash Flow | (181.9) | (89.8) | (172.1) | (90.0) | (4.6) | (1.1) | (33.3) |